All In Biotech

Drug Trial Radar · NCT06832540

Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects

Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Feb 19, 2025

Primary completion

Mar 5, 2025

Study completion Mar 5, 2025

Sponsor

Lead sponsor
Hangzhou PhecdaMed Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Mass Balance Study of \[14C\] TJ0113 in Healthy Chinese Subjects

Conditions

  • Healthy Chinese Subjects

Interventions

  • [14C]TJ0113Drug

    Subjects will receive a single oral dose of approximately 200 mg/100 μCi of the oral formulation of \[14C\] TJ0113 under fasted conditions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The excretion ratio of total radioactivity at each time interval and the cumulative recovery of total radioactivity in urine and fecesTime frame: Predose up to 240 hours after administration of [14C]TJ0113
  2. Pharmacokinetic parameters of total radioactivity in plasma: CmaxTime frame: Predose up to 168 hours after administration of [14C]TJ0113
  3. Pharmacokinetic parameters of total radioactivity in plasma: TmaxTime frame: Predose up to 168 hours after administration of [14C]TJ0113
  4. Pharmacokinetic parameters of total radioactivity in plasma: t1/2Time frame: Predose up to 168 hours after administration of [14C]TJ0113
  5. Pharmacokinetic parameters of total radioactivity in plasma: MRTTime frame: Predose up to 168 hours after administration of [14C]TJ0113
  6. Pharmacokinetic parameters of total radioactivity in plasma: AUCTime frame: Predose up to 168 hours after administration of [14C]TJ0113

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hospital of Jiangnan University

    Wuxi, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.